Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Donnerer, J; Grahovac, M; Stelzl, E; Kessler, HH; Bankuti, C; Stadlbauer, V; Stauber, RE.
Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy.
PHARMACOLOGY. 2006; 76(3): 136-140. Doi: 10.1159/000090942
Web of Science PubMed FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Donnerer Josef
Co-Autor*innen der Med Uni Graz
Kessler Harald
Putz-Bankuti Csilla
Stadlbauer-Köllner Vanessa
Stauber Rudolf
Stelzl Evelyn

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Therapeutic drug monitoring of ribavirin has been claimed to predict virological response and/or haematological side effects in patients with chronic hepatitis C undergoing peginterferon/ribavirin combination treatment. In the present study, steady-state ribavirin levels were retrospectively analyzed in serum samples from patients at week 12 of combination therapy with peginterferon alpha-2a or alpha-2b and ribavirin. Patients were classified as early virological responders on the basis of undetectable HCV-RNA or HCV-RNA drop >or=2 log from baseline at week 12. The mean ribavirin level was not different between early virological responders (2.3 +/- 0.1 microg/ml, n = 45) and early virological non-responders (2.0 +/- 0.2 microg/ml, n = 10). There was no correlation between ribavirin levels at week 12 and early virological response. In patients with early virological response, haemoglobin (Hb) levels were found to be decreased by 18% on average from the basal values; however, in only 2 patients Hb levels declined below 100 g/l. There was a moderate negative correlation between ribavirin levels and Hb levels at week 12 (R = -0.50, p < 0.001); however, ribavirin levels did not correlate with relative or absolute decline in Hb as compared to basal levels or with ribavirin dose per kilogram body weight. In addition, a significant negative correlation between ribavirin levels and glomerular filtration rate was found (R = -0.31, p < 0.05). Based on our results, monitoring of ribavirin serum levels at week 12 of HCV combination therapy does not appear to predict early virological response or reductions in Hb levels. Further research is needed to assess their diagnostic value at other time points of peginterferon/ribavirin combination treatment and/or in patients with renal insufficiency.
Find related publications in this database (using NLM MeSH Indexing)
Alanine Transaminase - blood
Antiviral Agents - blood Antiviral Agents - therapeutic use
Blood Preservation - methods
Chromatography, High Pressure Liquid - methods
Disease Progression -
Drug Monitoring -
Drug Therapy, Combination -
Female -
Glomerular Filtration Rate - physiology
Half-Life -
Hemoglobins - analysis
Hepatitis C, Chronic - blood Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology
Humans -
Interferon Alfa-2a - therapeutic use
Interferon Alfa-2b - therapeutic use
Male -
Middle Aged -
Polyethylene Glycols - therapeutic use
Polymerase Chain Reaction -
RNA, Viral - genetics
Retrospective Studies -
Ribavirin - blood Ribavirin - therapeutic use
Time Factors -
Treatment Outcome -

Find related publications in this database (Keywords)
ribavirin serum levels
chronic hepatitis C
© Med Uni Graz Impressum